Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Howard Chan
Institution:
Calvary Mater Newcastle Hospital
Observed institution:
Calvary Mater Newcastle Hospital
ORCID:
0000-0002-5802-5230
Observed ORCID:
0000-0002-5802-5230
OpenAlex ID:
A5133890531
Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial
2026
·
Adnan Nagrial
, Matteo S. Carlino
, et al.
·
Clinical Cancer Research
·
4
Data from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial
2026
·
Adnan Nagrial
, Matteo S. Carlino
, et al.
Supplementary Table S1 from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial
2026
·
Adnan Nagrial
, Matteo S. Carlino
, et al.
Abstract CT304: Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis
2026
·
Terrie-Anne Cock
, Sumitra Ananda
, et al.
·
Cancer Research
Show more works
View as search
Works count:
4
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type